中文(繁體)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

oxLDL in Diabetes Mellitus Patients and Disease Periodontal

只有註冊用戶可以翻譯文章
登陸註冊
鏈接已保存到剪貼板
狀態已完成
贊助商
Universidade Estadual Paulista Júlio de Mesquita Filho
合作者
LabviVale

關鍵詞

抽象

Periodontal disease (PD) and diabetes mellitus type 2 (DM2) have the same inflammatory etiopathogenesis and demonstrate a bidirectional relationship, for DM2 affects the severity of PD, and this may contribute to the overall inflammatory burden of the individual, influencing the natural course DM2. The aim of this study is to establish whether individuals with DM with or without chronic periodontitis have an increase in oxLDL and what is the influence of periodontal treatment in the reduction of oxLDL with consequent improvement in Diabetes Mellitus parameters.

描述

Periodontal disease (PD) and diabetes mellitus type 2 (DM2) have the same inflammatory etiopathogenesis and demonstrate a bidirectional relationship, for DM2 affects the severity of PD, and this may contribute to the overall inflammatory burden of the individual, influencing the natural course DM2. The aim of this study is to establish whether individuals with DM with or without chronic periodontitis have an increase in oxLDL and what is the influence of periodontal treatment in the reduction of oxLDL with consequent improvement in Diabetes Mellitus parameters. 44 patients will be divided into 2 groups: Diabetic Patients with Chronic Periodontitis (DM2DP) and Diabetic Patients without Chronic Periodontitis (DM2). The DM2DP group will receive periodontal debridement and DM2 group will be treated with supragingival scaling. Both groups receive board control every 3 months. At baseline, 3 and 6 months after treatment, will be held making the clinical periodontal parameters (plaque index, gingival index, probing depth, gingival recession relative clinical attachment level and Periodontal Inflamed Surface Area (PISA) index) and blood collection for assessment serum inflammatory markers (oxLDL, LDL, HDL, total cholesterol, triglyceride, Interleukin (IL) IL-6, IL-8, IL-10, Tumor Necrosis Factor (TNF-α) and CRP). Biochemical analyzes will be carried out by Z-scan technique. The data obtained before and after periodontal therapy will be analyzed using the Shapiro-Wilk test.

日期

最後驗證: 10/31/2018
首次提交: 02/05/2017
提交的預估入學人數: 06/21/2017
首次發布: 06/25/2017
上次提交的更新: 11/10/2018
最近更新發布: 11/13/2018
實際學習開始日期: 05/01/2016
預計主要完成日期: 08/25/2016
預計完成日期: 01/27/2017

狀況或疾病

Type 2 Diabetes Mellitus With Periodontal Disease

干預/治療

Procedure: Type 2 diabetes mellitus and periodontitis

-

手臂組

干預/治療
Sham Comparator: Type 2 diabetes mellitus and periodontitis
periodontal debridement in a single session.
Procedure: Type 2 diabetes mellitus and periodontitis
Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
No Intervention: Type 2 diabetes mellitus and without periodontitis
maintained every three months.

資格標準

有資格學習的年齡 35 Years 至 35 Years
有資格學習的性別All
接受健康志願者
標準

Inclusion Criteria:

- individuals older than 35 years with DM2 diagnosed for more than five years and HbA1c between 7% and 11%;

- be diagnosed with generalized chronic periodontitis: present at least 6 sites with periodontal pocket and loss of insertion above 5mm and two more bags with loss of insertion above 6mm;

- present at least 20 teeth;

- agree to participate in the study and sign the informed consent form

Exclusion Criteria:

- patients with cardiovascular diseases, cancer, gastrointestinal disorders, skin diseases, pregnancy, lactation, smoking, arthritis, lupus or other diseases of inflammatory origin;

- have undergone periodontal treatment in the last 12 months;

- have made use of antioxidant supplements, anti-inflammatories, or antibiotics within the previous 3 months;

- make use of medications that can alter the marking and concentration of oxLDL, for example, statins;

- have changed the medication for glycemic control in the last 3 months;

- present dental elements with pulpal or periapical inflammation.

結果

主要結果指標

1. Probing depth change [baseline, 90 and 180 days]

The change in the probing depth will be measure in millimeters before and after the treatment.

次要成果指標

1. oxLDL concentration Change [baseline and 180 days]

Change in concentration of oxLDL will be measured before and treatment.

2. LDL, HDL, Total cholesterol, Triacylglycerol [baseline and 180 days]

Blood concentration (g/ml) will be measured before and after periodontal therapy.

3. Plaque index [baseline, 90 and 180 days]

Number of teeth affected before and after periodontal treatment

4. Gingival index [baseline, 90 and 180 days]

number of teeth affected before and after periodontal treatment

5. Gingival Recession [baseline, 90 and 180 days]

Evaluated in millimeters before and after the treatment.

6. Clinical Attachment Level [baseline, 90 and 180 days]

Evaluated in millimeters before and after the treatment.

加入我們的臉書專頁

科學支持的最完整的草藥數據庫

  • 支持55種語言
  • 科學支持的草藥療法
  • 通過圖像識別草藥
  • 交互式GPS地圖-在位置標記草藥(即將推出)
  • 閱讀與您的搜索相關的科學出版物
  • 通過藥效搜索藥草
  • 組織您的興趣並及時了解新聞研究,臨床試驗和專利

輸入症狀或疾病,並閱讀可能有用的草藥,輸入草藥並查看其所針對的疾病和症狀。
*所有信息均基於已發表的科學研究

Google Play badgeApp Store badge